3D engineering for optic neuropathy treatment. Issue 1 (January 2021)

• Record Type: Journal Article
• Authors: Xuan, Wenjing; Moothedathu, Aji Alex; Meng, Tuo; Gibson, David C.; Zheng, Jinhua; Xu, Qingguo
• Is Part Of: Drug discovery today. Volume 26:Issue 1(2021)
• Page Start: 181
• Page End: 188
• Publication Date: 2021-01
• Subjects: Drugs -- Design -- Periodicals; Drugs -- Research -- Periodicals; 615.1
• DOI: 10.1016/j.drudis.2020.09.034
• Languages: English
• ISSNs: 1359-6446

Abstract

Highlights: 3D engineering for recapitulating ocular pathophysiology and retina development. The development of retina and its 3D model engineering for optic neuropathies. The application of pluripotent stem cells in disease modelling, drug screening, and cell and gene therapies. The perspectives of 3D models in new therapy development for optic neuropathies. Abstract : Ocular disorders, such as age-related macular degeneration (AMD), diabetic retinopathy (DR), retinitis pigmentosa (RP), and glaucoma, can cause irreversible visual loss, and affect the quality of life of millions of patients. However, only very few 3D systems can mimic human ocular pathophysiology, especially the retinal degenerative diseases, which involve the loss of retinal ganglion cells (RGCs), photoreceptors, or retinal pigment epithelial cells (RPEs). In this review, we discuss current progress in the 3D modeling of ocular tissues, and review the use of the aforementioned technologies for optic neuropathy treatment according to the categories of associated disease models and their applications in drug screening, mechanism studies, and cell and gene therapies.